Publications and Supporting Literature

ASH 2022

BEACON: A Phase 2, Randomized, Open Label Study of Bitoperin to Evaluate the Safety, Tolerability, Efficacy, and Protoporphyrin IX Concentrations in Participants with Erythropoietic Protoporphyria (EPP)